Phase II often signals end of line for trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 1
Volume 18
Issue 1

The largest numbers of trial terminations occur at phase II, especially if the trial is for a marketed therapy compared with a novel drug, according to an expert analysis in the Good Clinical Practice Journal.

The largest numbers of trial terminations occur at phase II, especially if the trial is for a marketed therapy compared with a novel drug, according to an expert analysis in the Good Clinical Practice Journal.

Authors Christine Blazynski and Tracy DeGregorio analyzed aborted phase II trials to assess the reasons and strategies behind companies’ decisions to end the research. They found that companies were quicker to pull the plug on a poorly enrolling trial of a marketed drug because the drug was not dependent upon the trial for time to market (GCPj 15, 2008).

The authors found two major drivers of trial termination: company-controlled and trial-related. A company may choose to end a trial because of a change in internal drug strategy or pipeline reprioritization. A trial may also come to an abrupt end if enrollment is deemed too slow.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content